India's Cough Syrup Crisis: A Call for Stricter Regulation

The World Health Organization urges India to strengthen its regulation of toxic cough syrups after the deaths of 24 children. Despite new export rules, gaps in domestic testing remain. The incident underlines ongoing challenges in ensuring medicine quality in a vast and complex market.

India is being urged to strengthen its regulation of toxic cough syrups, following a tragic incident where at least 24 children died after consuming a contaminated medicine. A World Health Organization official expressed concern over the enforcement gaps despite some recent progress.

The fatal cases were linked to Coldrif cough syrup produced by Sresan Pharma, containing diethylene glycol at levels vastly exceeding safety limits. This comes two years after global efforts to enhance safety measures, prompted by previous incidents involving similar toxins in medicines from India and Indonesia.

Although new rules require testing for exports, domestic products remain unregulated, highlighting a significant oversight. The WHO emphasizes the need for ongoing improvement within India's vast pharmaceutical landscape and calls for comprehensive testing during production. Previous promises of reform and accountability remain unmet, raising ethical and legal concerns.